Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Halozyme Therapeutics, a biopharmaceutical company, has announced that Roche has dosed the first patient in a Phase I pharmacokinetic clinical trial with a subcutaneous formulation using Enhanze technology of a biologic directed to a second Roche exclusive target. This has triggered a milestone payment under the agreement.
Subscribe to our email newsletter
In December 2006, Halozyme entered into an agreement with Roche to apply Halozyme’s Enhanze technology to Roche’s biological therapeutic compounds. Under the terms of the agreement, Roche paid Halozyme an initial payment for the application of its recombinant human enzyme, rHuPH20, to three pre-defined Roche biologic targets.
In December 2008, Roche selected a fourth biologic target and has the option to exclusively develop and commercialize rHuPH20 with an additional nine targets. Pending the successful achievement of a series of clinical, regulatory and sales events, Roche may pay Halozyme additional milestones as well as royalties on potential future product sales.
Under the collaboration, Roche has access to Halozyme’s expertise in developing and applying rHuPH20 to Roche targets. Roche obtained a worldwide, exclusive license to develop and commercialize product combinations of rHuPH20 and Roche target compounds resulting from the collaboration.
Jonathan Lim, president and CEO of Halozyme, said: This is the second clinical trial initiated by Roche within a short timeframe and illustrates the rapid and efficient approach Roche is taking to develop different biologicals simultaneously with Enhanze technology.